The role of heme in gene expression
スポンサーリンク
概要
著者
-
Tadashi Nagai
Division Of Hematology Department Of Medicine Jichi Medical University
-
Shigeru Sassa
The Rockefeller University
-
TADASHI Nagai
The Rockefeller University
関連論文
- 白血病 (特集 分子標的薬治療--癌から他疾患までの治癒をめざして) -- (疾患別分子標的薬治療の現状と今後の展望 悪性腫瘍)
- Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia : the JALSG AML95 study
- 輸血後鉄過剰症に対する ICL670 (deferasirox) 投与により造血能の回復が得られた骨髄異形成症候群
- 急性白血病の寛解導入における血小板輸血トリガー値の検討
- Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
- Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia : results of a prospective study in Japan
- 薬物療法 多剤併用化学療法 (特集 骨髄性白血病--病因・治療研究の進歩) -- (治療法の進歩)
- Clinical features of adult acute leukemia with 11q23 abnormalities in Japan : a co-operative multicenter study
- Maintenance and preemptive therapy with ganciclovir for cytomegalovirus colitis with extremely high antigenemia in adult T-cell leukemia
- Sperm cryopreservation in patients with hematologic malignancies
- フローサイトメトリを用いて骨髄移植後の微小残存病変を検出した急性骨髄性白血病
- 急性GVHDの補助的検査:granzyme Bおよびperforin細胞内染色の有用性
- 骨髄移植後にB型劇症肝炎を発症した急性骨髄性白血病の一例
- 当科におけるバーキットリンパ腫/白血病治療成績の向上
- イマチニブに対して Late Suboptimal Response を示した慢性期CML症例に対する治療選択
- Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma
- AA amyloidosis associated with macroglobulinemia
- The role of heme in gene expression
- Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia : a retrospective safety analysis
- Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase : results from the Japanese subgroup of ENESTnd
- ステロイド抵抗性移植片対宿主病に対する間葉系幹細胞を用いた新規治療のパイロット試験
- MDSの最新治療 (MDS(骨髄異形成症候群))
- Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL : a 36-month analysis of a phase I and II study
- Autologous Hematopoietic Recovery with Aberrant Antigen Expression after Allogeneic Bone Marrow Transplantation
- Prediction of Progression from Refractory Cytopenia with Unilineage Dysplasia by Analysis of Bone Marrow Blast Cell Composition